Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX11 vs Perjeta PK/Safety in Healthy Chinese Males
NCT04411550Phase 1Completed
- Sponsor
- Henlius
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pertuzumab in HER2-positive breast cancer (4 arms), sponsored by Henlius. Primary endpoints: Maximum Serum Concentration at Day 99, Area Under the Curve from time zero to last quantifiable concentration at Day 99 and 1 more. Started Jul 2020; status: completed.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04411550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411550.